Ianalumab is a BAFF-R antagonist, a biologic targeting the B-cell activating factor receptor. This page compares Ianalumab with other drugs in its class, including Belimumab (Benlysta) and Anifrolumab (Saphnelo).
Ianalumab Alternatives: How It Compares to Other Biologics for SLE
Hipa.ai Research · Source: ClinicalTrials.gov / AACT · Last updated: AI-augmented data · 0/6 curated
Source: ClinicalTrials.gov via AACT · Hipa.ai, 2026-05-07Download chart as PNG
The competitive landscape includes approved therapies like Belimumab (Benlysta) from 2011 and Anifrolumab (Saphnelo) from 2021. Ianalumab is not yet approved, while pipeline candidates Telitacicept, Atacicept, and Dapirolizumab-pegol are still in Phase 3 development, approximately 1-2 years behind the most recent approvals.
Quick comparison table
| Drug | Class | Approved indications | Dosing | Year approved | Lead pivotal endpoint | Annual cost (rough) |
|---|---|---|---|---|---|---|
| Ianalumab | BAFF-R antagonist | — | 300 mg subcutaneously monthly | Pipeline | — | — |
| Belimumab (Benlysta) | BLyS-specific inhibitor | systemic lupus erythematosus, lupus nephritis | 10 mg/kg IV every 2 weeks for 3 doses then every 4 weeks, or 200 mg SC once weekly | 2011 | 58% @ 52 weeks | $42k |
| Anifrolumab (Saphnelo) | Type I interferon receptor antagonist | systemic lupus erythematosus | 300 mg via intravenous infusion every 4 weeks or 120 mg via subcutaneous injection once weekly | 2021 | BICLA response: 47.8% @ Week 52 | $72k |
| Telitacicept (Tai'ai) | BLyS/APRIL dual inhibitor | — | 160 mg subcutaneously once weekly | Pipeline | — | — |
| Atacicept | Dual BAFF/APRIL inhibitor | — | — | Pipeline | — | — |
| Dapirolizumab-pegol | CD40L inhibitor | — | — | Pipeline | BICLA response: 49.5% @ Week 48 | — |
Cost estimates are list-price approximations and do not reflect rebates, formulary tier, or out-of-pocket costs after benefits. The class-typical lead-pivotal endpoint here is SRI-4 response; cells render each drug's actual pivotal endpoint, which may differ. The "Year approved" column shows the FDA approval year for systemic lupus erythematosus specifically — drugs approved for other indications first appear with their this-indication date, or as Pipeline if not yet approved for this indication. Cross-trial comparisons can mislead — head-to-head Phase-3 data (when present) is below.
Ianalumab vs Belimumab (Benlysta)
No head-to-head Phase-3 trial directly compares Ianalumab with Belimumab.
Cross-trial caveat: the two drugs were tested in different patient populations at different time points. Cross-trial comparisons of response rates can mislead — the only rigorous comparison is a head-to-head randomized trial.
Ianalumab vs Anifrolumab (Saphnelo)
No head-to-head Phase-3 trial directly compares Ianalumab with Anifrolumab.
Cross-trial caveat: the two drugs were tested in different patient populations at different time points. Cross-trial comparisons of response rates can mislead — the only rigorous comparison is a head-to-head randomized trial.
Pipeline alternatives
Several investigational IL-17 / IL-17-related drugs are currently in active Phase 3 development. These include Telitacicept and Dapirolizumab-pegol. Another investigational agent, Atacicept, sponsored by EMD Serono, is also undergoing Phase 3 studies, with its lead trial registered as NCT00624338.
Choosing between Ianalumab and its alternatives
Ianalumab, a BAFF-R antagonist, represents a distinct mechanistic approach for managing systemic lupus erythematosus (SLE). Its unique target may offer a therapeutic option for patients who have not achieved adequate disease control with other available biologics or for whom a different mechanism of action is deemed beneficial. As a newer agent, its role in the treatment algorithm continues to be defined, potentially offering an alternative for patients with specific disease profiles or those seeking different treatment pathways.
In contrast, clinicians may consider established biologics such as belimumab (Benlysta) or anifrolumab (Saphnelo). Belimumab, a BLyS-specific inhibitor, has demonstrated an SRI-4 response rate of 58% at 52 weeks in clinical trials, with dosing options including 10 mg/kg intravenously every 2 weeks for 3 doses then every 4 weeks, or 200 mg subcutaneously once weekly. Anifrolumab, a type I interferon receptor antagonist, achieved a BICLA response of 47.8% at Week 52, and is administered as 300 mg via intravenous infusion every 4 weeks or 120 mg via subcutaneous injection once weekly. The choice among these agents often depends on individual patient characteristics, specific disease manifestations, prior treatment responses, and considerations of their distinct mechanisms of action and established safety profiles.
This information is for educational purposes only and does not constitute medical advice. Clinical decisions regarding patient care should always be made by a qualified healthcare professional.
Sources and methodology
Trial data was pulled from the ClinicalTrials.gov registry via the AACT relational mirror maintained by the Clinical Trials Transformation Initiative. AACT data freshness: .
Cross-trial comparison limitations:drugs without a direct head-to-head trial are compared using each drug's own pivotal trial. These trials enrolled different patient populations at different time points and used different statistical analysis sets. Cross-trial response-rate differences should not be interpreted as proof that one drug is more effective than another.
Related drug pages on Hipa.ai
Not medical advice. This page summarizes publicly-reported clinical trial data for informational purposes. Treatment decisions belong with a qualified prescribing clinician who knows your medical history. Drug approvals, dosing, and safety profiles change over time — always confirm with the current FDA prescribing information.
ianalumabianalumab alternativesalternativescomparisonsystemic lupus erythematosusbiologic-sleianalumab vs belimumabianalumab vs anifrolumabianalumab vs telitaciceptianalumab vs ataciceptianalumab vs dapirolizumab-pegol